Safety of Mesenchymal Stromal Cells (MSCs) and Their Use in Oncology Patients
Mesenchymal Stem Cells and Cancer
Mesenchymal stromal cells (MSCs) have gained prominence as therapeutic tools in regenerative medicine due to their immunomodulatory properties and ability to support tissue repair. However, their potential use in oncology patients has raised concerns, as their high proliferation capacity and interaction with tumor microenvironments could theoretically favor phenotypes that promote cancer progression. This article examines the scientific basis for evaluating the safety of MSCs and their role in oncological contexts.
Cell Cycle Regulation: A Key Mechanism
Like all living cells, MSCs are subject to a regulated cell cycle that ensures proper replication and division. This cycle includes the phases G1, S, G2, and M, along with a G0 phase, where cells can remain metabolically active but non-proliferative.
Progression between these phases is controlled by molecular checkpoints that verify genomic integrity and ensure favorable external conditions for division. If errors or damage are detected, cells can pause their cycle to repair defects or undergo programmed cell death (apoptosis). However, when regulatory mechanisms fail, uncontrolled cell proliferation may occur, a hallmark of cancer.
Evaluating Cellular Stability
The safety of MSCs can be assessed using techniques like PCR, which measures the expression of genes involved in cell cycle regulation, such as *p53*, *p27*, and *p38*. Additionally, markers like *c-MYC*, *c-MYB*, and *KRAS*, often overexpressed in cancer, can be monitored to detect potential malignant transformations. This approach ensures that the cells used in therapies are safe and free of oncogenic risks.
Tumorigenic Potential: MSCs vs. Embryonic Stem Cells
Comparative studies show that MSCs exhibit a low tumorigenic risk compared to embryonic stem cells (ESCs). For instance, in murine models, ESC administration led to solid tumor formation within five weeks, whereas MSCs did not produce tumors even after 20 weeks. Furthermore, MSC-treated mice showed increased anti-inflammatory cytokines such as IL-10, suggesting a beneficial immunomodulatory effect.
Interactions with the Tumor Microenvironment
The tumor microenvironment is critical for cancer survival and progression, with tumor-associated fibroblasts (TAFs) playing a key role. Studies suggest that MSCs, particularly those derived from bone marrow (BM-MSCs), can differentiate into TAF-like phenotypes when exposed to tumor-derived signals, potentially supporting tumor growth. However, MSCs derived from Wharton’s jelly in the umbilical cord (UC-MSCs) exhibit greater resistance to this transformation, retaining their original phenotype and even inhibiting the proliferation of certain cancer cells.
Therapeutic Applications and Recommendations
Despite their low tumorigenic risk, the use of MSCs in oncology patients must be approached with caution. UC-MSCs have demonstrated potential to induce apoptosis in leukemic cells and reduce proliferation in cancers such as lung and liver cancer. However, MSC therapies are not intended as cancer treatments. Instead, they may be useful for addressing non-oncological conditions in carefully selected patients.
Thorough clinical case evaluation, review of scientific literature, and verification of cell source and quality are essential steps before MSC application.
Conclusions
Although preclinical studies support the safety of MSCs, it is crucial to recognize that in vitro and animal model results may not always translate directly to clinical settings. Baja Regenerative is committed to rigorous research and constant monitoring of cellular stability in its cultures, ensuring that physicians and patients can trust the safety and quality of our therapies.
MSCs represent a promising tool in regenerative medicine, but their use in oncology patients requires careful and ethical analysis. For more information about our therapies and advancements in this field, please contact us.
References
-Ciciró Y. y Sala A. MYB oncoproteins: Emerging players and potential therapeutic targets in human cancer. 2021. 10, 19.
-Gao F., et al. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Communication and Signaling. 2023. 21, 28
-Gauthaman K., et al. Extra-embryonic human Wharton’s jelly stem cells do not induce tumorogenesis, unlike human embryonic stem cells. Reproductive BioMedicine Online. 2012. 24, 235 – 246.
-Lin HD., et al. Human umbilical cord Wharton’s jelly stem cell conditioned médium induces tumoricidal effects on lymphoma cells through hydrogen peroxide mediation. J Cell Biochem. 2016. 117 (9), 2045 – 2055.
-Subramanian A., et al. Human umbilical cord Wharton’s Jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow messenchymal stem cells. Journal of Cellular Biochemistry. 2012. 113, 1886 – 1895.
-Tian K., et al. p38 MAPK contributes to the growth inhibition of leukemic tumor cells mediated by human umbilical cord mesenchymal stem cells. Cell Physiol Biochem. 2012. 26 (6), 799 – 808.
-Timar J. y Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. 2020. 39, 1029 – 1038.
